Communiqués Hepion Pharmaceuticals, Inc.

Actions

HEPA

US4268974015

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:41:39 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,0810 ^USD	-19,00%		-7,32%	+35,00%

20/08	Hepion Pharmaceuticals, Inc. annonce la nomination de James Liddy au poste de membre du conseil d'administration, à compter du 19 août 2026	CI
13/08	Hepion Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

03/03	Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma	AQ
25/06/25	Hepion Pharmaceuticals Successfully Completes Application to the OTCQB	AQ
16/06/25	Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer	AQ
12/05/25	Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq	AQ
07/05/25	Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC	AQ
14/03/25	Hepion Pharmaceuticals Announces Reverse Stock Split	AQ
22/01/25	Hepion Pharmaceuticals Announces $9.0 Million Public Offering	AQ
11/12/24	Hepion Pharmaceuticals : Announces Termination of Merger Agreement with Pharma Two B Ltd Form 8 K	PU
11/12/24	Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.	AQ
05/12/24	Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group	AQ
02/12/24	Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B	AQ
11/11/24	Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger	AQ
04/09/24	Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger	AQ
22/07/24	Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement	AQ
22/04/24	Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial	AQ
19/04/24	Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial	AQ
06/03/24	Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell	AQ
16/02/24	Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds	AQ
03/01/24	Hepion Pharmaceuticals to Present at NASH-TAG 2024	AQ
07/12/23	Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes	AQ
28/11/23	Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit	AQ
13/11/23	Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease	AQ
10/11/23	Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat	AQ
25/10/23	Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model	AQ
29/09/23	Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules	AQ